High dose Erythropoietin increases Brain Tissue Oxygen Tension in Severe Vasospasm after Subarachnoid Hemorrhage

BMC Neurology

Volumn 12, Issue , 2012, Pages

  Helbok, Raimund ^a   Shaker, Ehab ^a,b   Beer, Ronny ^a   Chemelli, Andreas ^a   Sojer, Martin ^a   Sohm, Florian ^a   Broessner, Gregor ^a   Lackner, Peter ^a   Beck, Monika ^a   Zangerle, Alexandra ^a   Pfausler, Bettina ^a   Thome, Claudius ^a   Schmutzhard, Erich ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Cerebral microdialysis; Erythropoietin; Multimodality monitoring; Subarachnoid hemorrhage

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; BRAIN METABOLISM; BRAIN OXYGEN TENSION; BRAIN PERFUSION; BRAIN TISSUE OXYGEN TENSION; BRAIN VASOSPASM; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; HUMAN; INTRACRANIAL PRESSURE; MALE; MEAN ARTERIAL PRESSURE; SINGLE DRUG DOSE; SUBARACHNOID HEMORRHAGE;

ADULT; AGED; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; OXYGEN; OXYGEN CONSUMPTION; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; VASOSPASM, INTRACRANIAL;

EID: 84861801737     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-12-32     Document Type: Article

References (25)

1. Bederson JB, Connolly ES, Batjer HH, Dacey RG, Dion JE, Diringer MN, Duldner JE, Harbaugh RE, Patel AB, Rosenwasser RH. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 2009, 40(3):994-1025. 10.1161/STROKEAHA.108.191395, 19164800.
2. Zhou Y, Martin RD, Zhang JH. Advances in experimental subarachnoid hemorrhage. Acta Neurochir Suppl 2011, 110(Pt 1):15-21.
3. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 2011, 10(7):618-625. 10.1016/S1474-4422(11)70108-9, 21640651.
4. Hansen-Schwartz J, Vajkoczy P, Macdonald RL, Pluta RM, Zhang JH. Cerebral vasospasm: looking beyond vasoconstriction. Trends Pharmacol Sci 2007, 28(6):252-256. 10.1016/j.tips.2007.04.002, 17466386.
5. Pluta RM. Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. Pharmacol Ther 2005, 105(1):23-56. 10.1016/j.pharmthera.2004.10.002, 15626454.
6. Ferro JM, Canhao P, Peralta R. Update on subarachnoid haemorrhage. J Neurol 2008, 255(4):465-479. 10.1007/s00415-008-0606-3, 18357424.
7. Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN, Brown S, Kirkpatrick PJ. Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg 2009, 111(1):171-180. 10.3171/2009.3.JNS081332, 19344224.
8. Springborg JB, Moller C, Gideon P, Jorgensen OS, Juhler M, Olsen NV. Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir (Wien) 2007, 149(11):1089-1101. discussion 1101.
9. Turner JD, Mammis A, Prestigiacomo CJ. Erythropoietin for the treatment of subarachnoid hemorrhage: a review. World Neurosurg 2010, 73(5):500-507. 10.1016/j.wneu.2010.02.026, 20920933.
10. Xiong Y, Chopp M, Lee CP. Erythropoietin improves brain mitochondrial function in rats after traumatic brain injury. Neurol Res 2009, 31(5):496-502. 10.1179/174313208X353703, 19099671.
11. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999, 19(6):643-651.
12. Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S, Masuda S, Sasaki R. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 1998, 253(1):26-32. 10.1006/bbrc.1998.9748, 9875214.
13. Marti HH. Erythropoietin and the hypoxic brain. J Exp Biol 2004, 207(Pt 18):3233-3242.
14. Maiese K, Chong ZZ, Hou J, Shang YC. Erythropoietin and oxidative stress. Curr Neurovasc Res 2008, 5(2):125-142. 10.2174/156720208784310231, 2570710, 18473829.
15. Jerndal M, Forsberg K, Sena ES, Macleod MR, O'Collins VE, Linden T, Nilsson M, Howells DW. A systematic review and meta-analysis of erythropoietin in experimental stroke. J Cereb Blood Flow Metab 2010, 30(5):961-968. 10.1038/jcbfm.2009.267, 2949185, 20040929.
16. Contaldo C, Elsherbiny A, Lindenblatt N, Plock JA, Trentz O, Giovanoli P, Menger MD, Wanner GA. Erythropoietin enhances oxygenation in critically perfused tissue through modulation of nitric oxide synthase. Shock 2009, 31(6):599-606.
17. Santhanam AV, Smith LA, Akiyama M, Rosales AG, Bailey KR, Katusic ZS. Role of endothelial NO synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasm. Stroke 2005, 36(12):2731-2737. 10.1161/01.STR.0000190021.85035.5b, 16269632.
18. Murphy AM, Xenocostas A, Pakkiri P, Lee TY. Hemodynamic effects of recombinant human erythropoietin on the central nervous system after subarachnoid hemorrhage: reduction of microcirculatory impairment and functional deficits in a rabbit model. J Neurosurg 2008, 109(6):1155-1164. 10.3171/JNS.2008.109.12.1155, 19035736.
19. Jaeger M, Soehle M, Schuhmann MU, Winkler D, Meixensberger J. Correlation of continuously monitored regional cerebral blood flow and brain tissue oxygen. Acta Neurochir (Wien) 2005, 147(1):51-56. discussion 56.
20. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004, 35(7):1732-1737. 10.1161/01.STR.0000132196.49028.a4, 15178821.
21. Marti HH, Bernaudin M, Petit E, Bauer C. Neuroprotection and Angiogenesis: Dual Role of Erythropoietin in Brain Ischemia. News Physiol Sci 2000, 15:225-229.
22. Cuzzocrea S, Di Paola R, Mazzon E, Patel NS, Genovese T, Muia C, Crisafulli C, Caputi AP, Thiemermann C. Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 2006, 34(4):1168-1177. 10.1097/01.CCM.0000207346.56477.E8, 16484922.
23. Vespa P, Bergsneider M, Hattori N, Wu HM, Huang SC, Martin NA, Glenn TC, McArthur DL, Hovda DA. Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. J Cereb Blood Flow Metab 2005, 25(6):763-774. 10.1038/sj.jcbfm.9600073, 15716852.
24. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007, 357(10):965-976. 10.1056/NEJMoa071533, 17804841.
25. Springborg JB, Ma X, Rochat P, Knudsen GM, Amtorp O, Paulson OB, Juhler M, Olsen NV. A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in rats. Br J Pharmacol 2002, 135(3):823-829. 10.1038/sj.bjp.0704521, 1573185, 11834631.